174 related articles for article (PubMed ID: 23674352)
1. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
Hamed HA; Yamaguchi Y; Fisher PB; Grant S; Dent P
J Cell Physiol; 2013 Oct; 228(10):1996-2005. PubMed ID: 23674352
[TBL] [Abstract][Full Text] [Related]
2. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
[TBL] [Abstract][Full Text] [Related]
3. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
4. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Hamed HA; Tavallai S; Grant S; Poklepovic A; Dent P
J Cell Physiol; 2015 Jan; 230(1):131-9. PubMed ID: 24911215
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
Tang Y; Yacoub A; Hamed HA; Poklepovic A; Tye G; Grant S; Dent P
Cancer Biol Ther; 2012 May; 13(7):567-74. PubMed ID: 22406992
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Zhang G; Park MA; Mitchell C; Hamed H; Rahmani M; Martin AP; Curiel DT; Yacoub A; Graf M; Lee R; Roberts JD; Fisher PB; Grant S; Dent P
Clin Cancer Res; 2008 Sep; 14(17):5385-99. PubMed ID: 18765530
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
Sajithlal GB; Hamed HA; Cruickshanks N; Booth L; Tavallai S; Syed J; Grant S; Poklepovic A; Dent P
Mol Pharmacol; 2013 Oct; 84(4):562-71. PubMed ID: 23877009
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
Chen CH; Chen MC; Wang JC; Tsai AC; Chen CS; Liou JP; Pan SL; Teng CM
Clin Cancer Res; 2014 Mar; 20(5):1274-1287. PubMed ID: 24520095
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
[TBL] [Abstract][Full Text] [Related]
11. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
12. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
13. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Wang W; Gallant JN; Katz SI; Dolloff NG; Smith CD; Abdulghani J; Allen JE; Dicker DT; Hong B; Navaraj A; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(3):229-38. PubMed ID: 21725212
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Sinicrope FA
Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Walker T; Mitchell C; Park MA; Yacoub A; Graf M; Rahmani M; Houghton PJ; Voelkel-Johnson C; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):342-55. PubMed ID: 19483104
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
Tan W; Zhu S; Cao J; Zhang L; Li W; Liu K; Zhong J; Shang C; Chen Y
Oncol Res; 2017 Nov; 25(9):1543-1553. PubMed ID: 28276313
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
Park MA; Zhang G; Mitchell C; Rahmani M; Hamed H; Hagan MP; Yacoub A; Curiel DT; Fisher PB; Grant S; Dent P
Mol Cancer Ther; 2008 Sep; 7(9):2633-48. PubMed ID: 18790746
[TBL] [Abstract][Full Text] [Related]
18. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
Meng XW; Lee SH; Dai H; Loegering D; Yu C; Flatten K; Schneider P; Dai NT; Kumar SK; Smith BD; Karp JE; Adjei AA; Kaufmann SH
J Biol Chem; 2007 Oct; 282(41):29831-46. PubMed ID: 17698840
[TBL] [Abstract][Full Text] [Related]
19. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
Koehler BC; Urbanik T; Vick B; Boger RJ; Heeger S; Galle PR; Schuchmann M; Schulze-Bergkamen H
World J Gastroenterol; 2009 Dec; 15(47):5924-35. PubMed ID: 20014456
[TBL] [Abstract][Full Text] [Related]
20. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
Li J; Chen Y; Wan J; Liu X; Yu C; Li W
Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
